FMP

FMP

Enter

TXMD - TherapeuticsMD, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/TXMD.png

TherapeuticsMD, Inc.

TXMD

NASDAQ

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

1.05 USD

0.0004 (0.03808%)

Latest TXMD News

Benzinga

Aug 26, 2024

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Read More

Zacks Investment Research

Apr 14, 2023

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More

Zacks Investment Research

Nov 14, 2022

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Read More

Zacks Investment Research

Aug 15, 2022

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Read More

Seeking Alpha

Aug 15, 2022

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript

TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator [Starts Abruptly] for the Therapeutics MD's Second Quarter 2022 Financial Results Conference Call.

Read More

Business Wire

Aug 8, 2022

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date:   Monday, August 15, 2022 Time:   8:30 a.m. ET

Read More

Benzinga

Jul 13, 2022

Why TherapeuticsMD Shares Are Sinking Today?

Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended deadline. TherapeuticsMD's products are.

Read More

Market Watch

Jul 13, 2022

TherapeuticsMD's stock falls 41% after tender offer expires

Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of TherapeuticsMD isn't expected to go through. The tender offer expired Tuesday.

Read More

Benzinga

Jun 21, 2022

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Read More

Seeking Alpha

Jun 16, 2022

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD's $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep